Navigating research peptide sourcing requires absolute analytical transparency. PX1 Research provides third-party tested Thymosin Alpha-1 verified via RP-HPLC, Mass Spectrometry, and endotoxin assays to ensure reproducible experimental data in preclinical research settings.
Navigating research peptide sourcing requires absolute analytical transparency. PX1 Research provides third-party tested Thymosin Alpha-1 verified via RP-HPLC, Mass Spectrometry, and endotoxin assays to ensure reproducible experimental data in preclinical research settings.
Third-party tested Thymosin Alpha-1 refers to synthetic Thymosin Alpha-1 (a 28-amino-acid peptide) that has undergone independent laboratory analytical verification prior to research distribution. This verification ensures sequence identity, precise molecular mass determination, chromatographic purity levels exceeding 99.0%, and low endotoxin levels suitable for sensitive biological assays.
In cell culture and animal models, unverified impurities or trace endotoxins can artifactually stimulate Toll-like receptors or induce cytokine cascades, compromising experimental integrity. PX1 Research submits every synthesis batch of Thymosin Alpha-1 10mg to ISO 17025-accredited US laboratories. Each batch receives a public Certificate of Analysis (COA) detailing reverse-phase high-performance liquid chromatography (RP-HPLC) chromatograms, electrospray ionization mass spectrometry (ESI-MS) spectra, and Chromogenic LAL endotoxin quantification.
Thymosin Alpha-1 (TA1), also recognized in biochemical literature as Thymalfasin, is an N-terminally acetylated peptide fragment corresponding to positions 1 through 28 of thymosin fraction 5. Its chemical structure features the empirical formula C129H215N33O55 with a calculated molecular mass of approximately 3108.3 Da. Originally isolated from bovine thymic tissue, modern research utilizes synthetic solid-phase peptide synthesis (SPPS) to yield a highly pure, consistent sequence.
The primary sequence of Thymosin Alpha-1—Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH—contains a high proportion of acidic residues (glutamic acid and aspartic acid). This structural motif grants the compound distinct hydrophilic characteristics and an acidic isoelectric point, requiring precise mobile-phase adjustments during HPLC purification to achieve consistent separation from truncated synthesis deletion sequences.
Preclinical investigation into Thymosin Alpha-1 focuses heavily on its immunomodulatory signaling mechanisms across mammalian cellular models. In vitro assays demonstrate that TA1 interacts directly with Toll-like receptor 7 (TLR7) and Toll-like receptor 9 (TLR9) signaling cascades in dendritic cells and macrophages. This interaction downstream activates Nuclear Factor Kappa B (NF-κB) and MyD88-dependent pathways, facilitating the maturation of antigen-presenting cells.
In rodent models, research indicates that Thymosin Alpha-1 upregulation increases the activity and differentiation of CD4+ and CD8+ T-lymphocytes, as well as natural killer (NK) cells. Experimental evidence suggests that TA1 modulates cytokine production by enhancing interleukin-2 (IL-2), interferon-gamma (IFN-γ), and interleukin-12 (IL-12) expressions while regulating pro-inflammatory signaling in hyper-inflammatory challenge models. Researchers interested in broader peptide classifications can explore our comprehensive thymosin peptides overview and our broader catalog of research peptides.
Determining the purity of synthetic Thymosin Alpha-1 relies on two non-negotiable analytical techniques: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). RP-HPLC separates the main peptide peak from synthesis deletion sequences, side-reaction byproducts, and residual protecting groups. A valid Certificate of Analysis displays a clean single peak with a total peak area integrated at >99.0%.
Mass Spectrometry serves as the definitive identity check. ESI-MS measures the mass-to-charge ratio (m/z) of the ionized peptide. Because synthesis errors can occasionally yield an identical HPLC retention time for closely related sequence variants, the MS spectrum confirms the exact molecular weight of 3108.3 Da. To learn more about interpreting these technical analytical reports, visit our detailed guide on peptide purity testing standards.
For researchers conducting in vitro cellular cultures or in vivo rodent studies, bacterial endotoxin content (lipopolysaccharide, LPS) is a critical variable. Endotoxins present in low-quality lyophilized powders trigger non-specific inflammatory signaling via TLR4 pathways, which can completely mask or invalidate the biological effects of the peptide under study.
PX1 Research ensures that every batch of third-party tested Thymosin Alpha-1 undergoes quantitative Limulus Amebocyte Lysate (LAL) testing. Our standard threshold limits endotoxin levels to under 0.01 EU/mg. Maintaining strict endotoxin boundaries guarantees that signal transduction, cytokine expression, and cellular survival data recorded during investigations are directly attributable to the peptide mechanism rather than bacterial contaminants.
Within preclinical research into regulatory and restorative peptides, Thymosin Alpha-1 is frequently evaluated alongside other thymic and biological response modifiers. While TA1 predominantly targets early T-cell maturation and TLR7/9 signaling pathways, Thymosin Beta-4 acts primarily as an actin-sequestering protein fragment involved in cell migration and tissue remodeling. Similarly, antimicrobial and immunomodulatory host defense peptides like LL-37 operate through direct membrane disruption and formyl peptide receptor signaling, whereas gastroprotective compounds like BPC-157 influence nitric oxide pathways and angiogenic growth factor expression.
Understanding these distinct mechanism profiles allows research teams to select appropriate compounds or construct comparative cross-treatment arms in experimental protocols. Comprehensive documentation for all target compounds is cataloged in the PX1 research library.
Thymosin Alpha-1 is supplied as a sterile, lyophilized (freeze-dried) powder to maximize chemical stability during transport and storage. For optimal preservation, unconstituted vials should be stored at -20°C or -80°C in a desiccated environment. Lyophilized powder stored under these conditions maintains stability for up to 24 months.
When preparing solutions for laboratory experimentation, reconstitution should be performed under a laminar flow hood using sterile laboratory-grade solvents, such as Bacteriostatic Water (0.9% benzyl alcohol) or Sterile 0.9% Sodium Chloride Injection. The solvent should be gently directed along the inner glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl agitation—never violent vortexing—is recommended to prevent mechanical shearing of the peptide structure. Once reconstituted, liquid solutions should be aliquoted into single-use polypropylene tubes to prevent repeated freeze-thaw cycles and stored at 2°C to 8°C for short-term use (up to 30 days) or -20°C for extended study protocols.
Reliable experimental outcomes depend entirely on batch-to-batch consistency and complete supply chain transparency. PX1 Research manufactures all research compounds within GMP-compliant, USA-based facilities. Each production lot of Thymosin Alpha-1 is assigned a unique tracking number linked directly to its corresponding analytical documentation.
Institutional laboratories, academic facilities, and commercial research entities ordering through our bulk lab accounts receive full access to lot-specific analytical reports. Orders placed before cut-off times ship same-day from our centralized distribution facilities in California and Arizona, ensuring minimal transit degradation and immediate availability for planned research schedules.
What purity level is required for Thymosin Alpha-1 research?
Preclinical in vitro and in vivo models require a minimum RP-HPLC purity of 98.0%, though >99.0% is preferred to prevent non-specific baseline activity caused by peptide synthesis fragments.
How do I verify the third-party testing for my batch of Thymosin Alpha-1?
Every PX1 Research product vial includes a batch number. You can verify your compound by downloading the lot-specific Certificate of Analysis (COA) directly from our website, which displays raw RP-HPLC chromatograms, mass spectrometry reports, and endotoxin assay results.
What solvent is recommended for reconstituting Thymosin Alpha-1 for lab use?
Sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4) are commonly used solvents depending on the downstream assay requirement. For cell culture assays sensitivity to benzyl alcohol, sterile normal saline or PBS is recommended.
What is the molecular weight of Thymosin Alpha-1?
The calculated molecular weight of synthetic Thymosin Alpha-1 (28 amino acids, N-terminally acetylated) is 3108.3 Da, which should be confirmed by Mass Spectrometry.
What are the endotoxin limits for PX1 Research peptides?
PX1 Research verifies that endotoxin levels in our research peptides are tested via LAL assay and remain under 0.01 EU/mg to ensure compatibility with cellular assays.
How should reconstituted Thymosin Alpha-1 be stored in the lab?
Reconstituted solutions should be divided into single-use aliquots and stored at -20°C or -80°C to avoid degraded activity caused by repeated freeze-thaw cycles. Short-term refrigerated storage (2°C to 8°C) is suitable for up to 30 days.
Is Thymosin Alpha-1 identical to Thymosin Beta-4?
No. Thymosin Alpha-1 (28 amino acids) and Thymosin Beta-4 (43 amino acids) are distinct peptides derived from different parent proteins with separate molecular weights, primary structures, and biological signaling targets.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based facilities and dispatched directly from primary logistics hubs located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.